CLINICAL TRIALS PROFILE FOR FAMITINIB

Clinical Trials for Famitinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01392235 ↗	Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)	Completed	Sun Yat-sen University	Phase 2	RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable. PURPOSE: This phase II trial is studying how well famitinib works in treating patients with recurrent and/or metastatic NPC.
NCT01392235 ↗	Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)	Completed	Jiangsu HengRui Medicine Co., Ltd.	Phase 2	RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable. PURPOSE: This phase II trial is studying how well famitinib works in treating patients with recurrent and/or metastatic NPC.
NCT01462474 ↗	Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma	Completed	Sun Yat-sen University	Phase 1	RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study of mono famitinib has shown that the drug's toxicity is manageable. PURPOSE: This phase I trial is studying the safety and tolerance of concurrent chemoradiotherapy with famitinib for patients with locally advanced nasopharyngeal carcinoma.
NCT01462474 ↗	Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma	Completed	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study of mono famitinib has shown that the drug's toxicity is manageable. PURPOSE: This phase I trial is studying the safety and tolerance of concurrent chemoradiotherapy with famitinib for patients with locally advanced nasopharyngeal carcinoma.
NCT01653574 ↗	A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer	Completed	Jiangsu HengRui Medicine Co., Ltd.	Phase 2	The hypothesis of this clinical research study is to discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated HER2-negative metastatic breast cancer.
NCT01653574 ↗	A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer	Completed	Fudan University	Phase 2	The hypothesis of this clinical research study is to discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated HER2-negative metastatic breast cancer.

Clinical Trial Conditions for Famitinib

Condition Name

Condition Name for
Intervention	Trials
Solid Tumor	4
Triple-Negative Breast Cancer	3
Colorectal Cancer Metastatic	2
Colorectal Cancer Recurrent	2

Condition MeSH

Condition MeSH for
Intervention	Trials
Breast Neoplasms	11
Lung Neoplasms	7
Carcinoma, Non-Small-Cell Lung	6
Carcinoma	5

Clinical Trial Locations for Famitinib

Trials by Country

Trials by Country for
Location	Trials
China	55

Clinical Trial Progress for Famitinib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	26
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Not yet recruiting	22
Completed	10
Recruiting	8

Clinical Trial Sponsors for Famitinib

Sponsor Name

Sponsor Name for
Sponsor	Trials
Jiangsu HengRui Medicine Co., Ltd.	38
Fudan University	9
Sun Yat-sen University	4

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	38
Other	26